Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Total Debt over the past 6 years, most recently at $13.5 million for Q3 2025.

  • Quarterly results put Total Debt at $13.5 million for Q3 2025, down 52.17% from a year ago — trailing twelve months through Sep 2025 was $13.5 million (down 52.17% YoY), and the annual figure for FY2024 was $24.6 million, down 16.23%.
  • Total Debt for Q3 2025 was $13.5 million at Rani Therapeutics Holdings, down from $17.2 million in the prior quarter.
  • Over the last five years, Total Debt for RANI hit a ceiling of $29.5 million in Q2 2024 and a floor of $30000.0 in Q2 2022.
  • Median Total Debt over the past 5 years was $22.8 million (2024), compared with a mean of $18.1 million.
  • Biggest five-year swings in Total Debt: tumbled 96.66% in 2021 and later surged 97450.0% in 2023.
  • Rani Therapeutics Holdings' Total Debt stood at $126000.0 in 2021, then skyrocketed by 23034.13% to $29.1 million in 2022, then grew by 0.8% to $29.4 million in 2023, then fell by 16.23% to $24.6 million in 2024, then plummeted by 45.0% to $13.5 million in 2025.
  • The last three reported values for Total Debt were $13.5 million (Q3 2025), $17.2 million (Q2 2025), and $20.9 million (Q1 2025) per Business Quant data.